Pharvaris Advances in HAE Treatment with Strong Financials

Pharvaris (PHVS) has released an update.

Pharvaris, a biopharmaceutical company, reported a robust financial position with €305 million in cash, as it progresses its pivotal Phase 3 studies for the treatment and prevention of hereditary angioedema (HAE) using deucrictibant. The company is poised for significant advancements with its novel oral therapy, showcasing promising long-term data for both prophylactic and on-demand HAE treatments. These developments place Pharvaris at the forefront of addressing unmet needs in the HAE treatment landscape.

For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.